Demographic and health characteristics of 3,4-methylenedioxymethamphetamine users (MDMA, ecstasy)

被引:1
|
作者
Wieckiewicz, Gniewko [1 ]
Danel, Dariusz [2 ]
Piegza, Magdalena [1 ]
Gorczyca, Piotr [1 ]
Pudlo, Robert [1 ]
机构
[1] Slaski Uniwersytet Med Katowicach, Wydzial Nauk Med Zabrze, Katedra & Oddzial Klin Psychiat, Ul Pyskowicka 49, PL-42612 Katowice, Poland
[2] Polish Acad Sci, Inst Immunol & Terapii Doswiadczalnej Ludwika Hir, Poznan, Poland
关键词
HADS; MDMA; GHQ-28; SUBJECTIVE EXPERIENCES; CARE;
D O I
10.12740/PP/OnlineFirst/134317
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Aim. MDMA is one of the most commonly used drugs in the world. Clinical studies are currently being conducted around the world on the use of this substance in the treatment of PTSD and alcoholism. However, little demographic information is available on users who use the substance for non-medical purposes. The aim of the study was to determine basic demographic and health characteristics with validated tools. Method. The authors prepared an original questionnaire on the demography of MDMA users and combined it with the General Health Questionnaire-28 (GHQ-28) and the Hospital Anxiety and Depression Scale (HADS). The survey was sent to Polish MDMA users via the Internet. Results. 304 responses were received from people over 18 years of age. MDMA is widespread among young adults, in many different places of residence and regardless of gender. The users take MDMA in both pill and crystal form and very rarely test drugs bought from a dealer. Most users feel that MDMA has had a good impact on their lives. Conclusions. MDMA is rarely used as the only psychoactive substance. MDMA users rate their health higher than people using other psychoactive substances.
引用
收藏
页码:1109 / 1130
页数:22
相关论文
共 50 条
  • [11] The Agony of Ecstasy: MDMA (3,4-Methylenedioxymethamphetamine) and the Kidney
    Campbell, Garland A.
    Rosner, Mitchell H.
    [J]. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2008, 3 (06): : 1852 - 1860
  • [12] NEUROCHEMISTRY AND NEUROTOXICITY OF 3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA, ECSTASY)
    MCKENNA, DJ
    PEROUTKA, SJ
    [J]. JOURNAL OF NEUROCHEMISTRY, 1990, 54 (01) : 14 - 22
  • [13] Adverse reactions with 3,4-methylenedioxymethamphetamine (MDMA; 'ecstasy')
    McCann, UD
    Slate, SO
    Ricaurte, GA
    [J]. DRUG SAFETY, 1996, 15 (02) : 107 - 115
  • [14] The cardiovascular effects of ecstasy (3,4-methylenedioxymethamphetamine, MDMA)
    Lester, SJ
    Baggott, MJ
    Viloria, EM
    Welm, S
    Schiller, NB
    Mendelson, J
    Jones, RT
    Foster, E
    [J]. CIRCULATION, 1999, 100 (18) : 575 - 575
  • [15] 3,4-methylenedioxymethamphetamine (MDMA, or ''ecstasy'') and associated hypoglycemia
    Montgomery, H
    Myerson, S
    [J]. AMERICAN JOURNAL OF EMERGENCY MEDICINE, 1997, 15 (02): : 218 - 218
  • [16] 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and driving impairment
    Logan, BK
    Couper, FJ
    [J]. JOURNAL OF FORENSIC SCIENCES, 2001, 46 (06) : 1426 - 1433
  • [17] False-Positive Amphetamine/Ecstasy (MDMA/3,4-Methylenedioxymethamphetamine) (CEDIA) and Ecstasy (MDMA/3,4-Methylenedioxymethamphetamine) (DRI) Test Results With Fenofibrate
    Kaplan, Yusuf Cem
    Erol, Almila
    Karadas, Baris
    [J]. THERAPEUTIC DRUG MONITORING, 2012, 34 (05) : 493 - 495
  • [18] Cannabis and Ecstasy/MDMA (3,4-methylenedioxymethamphetamine): an analysis of their neuropsychobiological interactions in recreational users
    A. C. Parrott
    R. M. Milani
    E. Gouzoulis-Mayfrank
    J. Daumann
    [J]. Journal of Neural Transmission, 2007, 114 : 959 - 968
  • [19] Cannabis and ecstasy/MDMA (3,4-methylenedioxymethamphetamine): an analysis of their neuropsychobiological interactions in recreational users
    Parrott, A. C.
    Milani, R. M.
    Gouzoulis-Mayfrank, E.
    Daumann, J.
    [J]. JOURNAL OF NEURAL TRANSMISSION, 2007, 114 (08) : 959 - 968
  • [20] A review on the mitochondrial toxicity of "ecstasy" (3,4-methylenedioxymethamphetamine, MDMA)
    Capela, Joao Paulo
    Carvalho, Felix Dias
    [J]. CURRENT RESEARCH IN TOXICOLOGY, 2022, 3